Keyphrases
Sickle Cell Disease
100%
Heparin Cofactor II
50%
Thrombin
39%
Dermatan Sulfate
32%
Heparin
25%
Rituximab
25%
Arginine
24%
Iron Deficiency
21%
Bleeding
21%
Lysine
19%
Deep Vein Thrombosis
18%
Cysteinyl Leukotrienes
16%
Clinical Utility
16%
Thrombotic Thrombocytopenic Purpura
16%
Age-related
16%
Metabolic Stress
16%
Iron Chelation Therapy
16%
Quality of Life
16%
Catheter-directed Thrombolysis
16%
Reticulocyte Hemoglobin Content
16%
Leukotriene B4 (LTB4)
15%
Glycosaminoglycans
14%
Remission
14%
Plasmapheresis
13%
Recombinant
12%
Complementary DNA (cDNA)
12%
Acute Chest Syndrome
12%
Adult Patients
12%
Heparin Sulfate
12%
Health Care Costs
12%
Sickle Cell Anemia
11%
Warfarin
10%
Myelodysplastic Syndrome
10%
Massive Bleeding
10%
Rare Occurrence
10%
Ferritin
10%
Relapsed or Refractory
10%
Anemia
10%
Nitroaniline
9%
Multiple Myeloma
9%
Immunosuppressive Therapy
9%
Prophylactic Treatment
9%
Hydroxyurea
9%
Heparin Binding
9%
Avascular Necrosis
9%
Reactive Sites
9%
Restriction Fragment Length Polymorphism
9%
Sustained Response
9%
Cyclophosphamide
9%
Immunosuppression
9%
Medicine and Dentistry
Sickle-Cell Disease
67%
Patient with Sickle Cell Disease
27%
Immunosuppressive Treatment
20%
Disease
19%
Bleeding
17%
Metabolic Stress
16%
Iron Deficiency
16%
Idiopathic Thrombocytopenic Purpura
16%
Sickle Cell
16%
Sickle Cell Trait
16%
Rituximab
16%
Chemotherapy
15%
Transplantation
14%
Acute Chest Syndrome
12%
Combination Therapy
12%
Health Care Cost
12%
Plasmapheresis
11%
Anemia
10%
Iron Overload
10%
Thrombosis
10%
Immunity
10%
Blood Transfusion
10%
Pediatrics
10%
Heparin
10%
Prophylaxis
9%
Cyclophosphamide
9%
Hydroxyurea
9%
Avascular Necrosis
9%
Injury
8%
Sulfhemoglobinemia
8%
Infarction
8%
Hematology
8%
Iron Metabolism
8%
Bleeding Disorder
8%
Antiphospholipid Syndrome
8%
Leukotriene E4
8%
Urinary System
8%
Telomerase Reverse Transcriptase
8%
High-Performance Liquid Chromatography
8%
Wheeze
8%
Asthma
8%
Digestive System Surgery
8%
Emergency Department
8%
Reticulocyte
8%
Escherichia coli
8%
Lung Transplantation
8%
Copper Deficiency
8%
Brain Metastasis
8%
Thrombotic Thrombocytopenic Purpura
8%
Acute Graft Versus Host Disease
8%
